The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling.
Animals
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Aurora Kinase B
/ metabolism
Azoxymethane
/ toxicity
Carcinogenesis
/ genetics
Cell Line, Tumor
Chromosomal Instability
Colon
/ cytology
Colorectal Neoplasms
/ chemically induced
Cytogenetic Analysis
Dextrans
/ toxicity
Drug Resistance, Neoplasm
/ genetics
Female
Gene Expression Regulation, Neoplastic
Gene Knockdown Techniques
Humans
Intestinal Mucosa
/ cytology
Male
Mice
Mice, Transgenic
Neoplasms, Experimental
/ chemically induced
Organoids
Primary Cell Culture
Proto-Oncogene Proteins c-myc
/ metabolism
RNA, Long Noncoding
/ genetics
RNA-Binding Proteins
/ genetics
Signal Transduction
/ genetics
Aneuploidy
MSS
Noncoding RNA
Tumorigenesis
Journal
Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
20
08
2019
revised:
10
08
2020
accepted:
11
08
2020
pubmed:
18
8
2020
medline:
16
4
2021
entrez:
18
8
2020
Statut:
ppublish
Résumé
Chromosomal instability (CIN) is a carcinogenesis event that promotes metastasis and resistance to therapy by unclear mechanisms. Expression of the colon cancer-associated transcript 2 gene (CCAT2), which encodes a long noncoding RNA (lncRNA), associates with CIN, but little is known about how CCAT2 lncRNA regulates this cancer enabling characteristic. We performed cytogenetic analysis of colorectal cancer (CRC) cell lines (HCT116, KM12C/SM, and HT29) overexpressing CCAT2 and colon organoids from C57BL/6N mice with the CCAT2 transgene and without (controls). CRC cells were also analyzed by immunofluorescence microscopy, γ-H2AX, and senescence assays. CCAT2 transgene and control mice were given azoxymethane and dextran sulfate sodium to induce colon tumors. We performed gene expression array and mass spectrometry to detect downstream targets of CCAT2 lncRNA. We characterized interactions between CCAT2 with downstream proteins using MS2 pull-down, RNA immunoprecipitation, and selective 2'-hydroxyl acylation analyzed by primer extension analyses. Downstream proteins were overexpressed in CRC cells and analyzed for CIN. Gene expression levels were measured in CRC and non-tumor tissues from 5 cohorts, comprising more than 900 patients. High expression of CCAT2 induced CIN in CRC cell lines and increased resistance to 5-fluorouracil and oxaliplatin. Mice that expressed the CCAT2 transgene developed chromosome abnormalities, and colon organoids derived from crypt cells of these mice had a higher percentage of chromosome abnormalities compared with organoids from control mice. The transgenic mice given azoxymethane and dextran sulfate sodium developed more and larger colon polyps than control mice given these agents. Microarray analysis and mass spectrometry indicated that expression of CCAT2 increased expression of genes involved in ribosome biogenesis and protein synthesis. CCAT2 lncRNA interacted directly with and stabilized BOP1 ribosomal biogenesis factor (BOP1). CCAT2 also increased expression of MYC, which activated expression of BOP1. Overexpression of BOP1 in CRC cell lines resulted in chromosomal missegregation errors, and increased colony formation, and invasiveness, whereas BOP1 knockdown reduced viability. BOP1 promoted CIN by increasing the active form of aurora kinase B, which regulates chromosomal segregation. BOP1 was overexpressed in polyp tissues from CCAT2 transgenic mice compared with healthy tissue. CCAT2 lncRNA and BOP1 mRNA or protein were all increased in microsatellite stable tumors (characterized by CIN), but not in tumors with microsatellite instability compared with nontumor tissues. Increased levels of CCAT2 lncRNA and BOP1 mRNA correlated with each other and with shorter survival times of patients. We found that overexpression of CCAT2 in colon cells promotes CIN and carcinogenesis by stabilizing and inducing expression of BOP1 an activator of aurora kinase B. Strategies to target this pathway might be developed for treatment of patients with microsatellite stable colorectal tumors.
Sections du résumé
BACKGROUND & AIMS
Chromosomal instability (CIN) is a carcinogenesis event that promotes metastasis and resistance to therapy by unclear mechanisms. Expression of the colon cancer-associated transcript 2 gene (CCAT2), which encodes a long noncoding RNA (lncRNA), associates with CIN, but little is known about how CCAT2 lncRNA regulates this cancer enabling characteristic.
METHODS
We performed cytogenetic analysis of colorectal cancer (CRC) cell lines (HCT116, KM12C/SM, and HT29) overexpressing CCAT2 and colon organoids from C57BL/6N mice with the CCAT2 transgene and without (controls). CRC cells were also analyzed by immunofluorescence microscopy, γ-H2AX, and senescence assays. CCAT2 transgene and control mice were given azoxymethane and dextran sulfate sodium to induce colon tumors. We performed gene expression array and mass spectrometry to detect downstream targets of CCAT2 lncRNA. We characterized interactions between CCAT2 with downstream proteins using MS2 pull-down, RNA immunoprecipitation, and selective 2'-hydroxyl acylation analyzed by primer extension analyses. Downstream proteins were overexpressed in CRC cells and analyzed for CIN. Gene expression levels were measured in CRC and non-tumor tissues from 5 cohorts, comprising more than 900 patients.
RESULTS
High expression of CCAT2 induced CIN in CRC cell lines and increased resistance to 5-fluorouracil and oxaliplatin. Mice that expressed the CCAT2 transgene developed chromosome abnormalities, and colon organoids derived from crypt cells of these mice had a higher percentage of chromosome abnormalities compared with organoids from control mice. The transgenic mice given azoxymethane and dextran sulfate sodium developed more and larger colon polyps than control mice given these agents. Microarray analysis and mass spectrometry indicated that expression of CCAT2 increased expression of genes involved in ribosome biogenesis and protein synthesis. CCAT2 lncRNA interacted directly with and stabilized BOP1 ribosomal biogenesis factor (BOP1). CCAT2 also increased expression of MYC, which activated expression of BOP1. Overexpression of BOP1 in CRC cell lines resulted in chromosomal missegregation errors, and increased colony formation, and invasiveness, whereas BOP1 knockdown reduced viability. BOP1 promoted CIN by increasing the active form of aurora kinase B, which regulates chromosomal segregation. BOP1 was overexpressed in polyp tissues from CCAT2 transgenic mice compared with healthy tissue. CCAT2 lncRNA and BOP1 mRNA or protein were all increased in microsatellite stable tumors (characterized by CIN), but not in tumors with microsatellite instability compared with nontumor tissues. Increased levels of CCAT2 lncRNA and BOP1 mRNA correlated with each other and with shorter survival times of patients.
CONCLUSIONS
We found that overexpression of CCAT2 in colon cells promotes CIN and carcinogenesis by stabilizing and inducing expression of BOP1 an activator of aurora kinase B. Strategies to target this pathway might be developed for treatment of patients with microsatellite stable colorectal tumors.
Identifiants
pubmed: 32805281
pii: S0016-5085(20)35057-5
doi: 10.1053/j.gastro.2020.08.018
pmc: PMC7725986
mid: NIHMS1622361
pii:
doi:
Substances chimiques
BOP1 protein, human
0
Dextrans
0
MYC protein, human
0
Proto-Oncogene Proteins c-myc
0
RNA, Long Noncoding
0
RNA-Binding Proteins
0
long non-coding RNA CCAT2, human
0
AURKB protein, human
EC 2.7.11.1
Aurora Kinase B
EC 2.7.11.1
Azoxymethane
MO0N1J0SEN
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
2146-2162.e33Subventions
Organisme : NIGMS NIH HHS
ID : R35 GM126942
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA202797
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA096297
Pays : United States
Organisme : NCATS NIH HHS
ID : UH3 TR000943
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA211121
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA096300
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM121487
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA072851
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA182905
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA222007
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA051008
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM122775
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA181572
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA243707
Pays : United States
Informations de copyright
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.
Références
Nat Med. 2011 Oct 23;17(11):1514-20
pubmed: 22019887
Cancer Inform. 2017 Dec 13;16:1176935117746637
pubmed: 29343938
Semin Cancer Biol. 2007 Feb;17(1):5-18
pubmed: 17126026
Nat Rev Genet. 2012 Jan 24;13(3):189-203
pubmed: 22269907
Chromosoma. 2013 Dec;122(6):487-97
pubmed: 24022641
Nature. 1994 Sep 22;371(6495):297-300
pubmed: 8090199
Genome Res. 2018 Apr;28(4):432-447
pubmed: 29567676
Biochim Biophys Acta. 2009 Oct;1790(10):963-9
pubmed: 19344750
Genome Res. 2002 Jun;12(6):996-1006
pubmed: 12045153
Proc Natl Acad Sci U S A. 2014 Sep 23;111(38):E3996-4005
pubmed: 25201961
Clin Cancer Res. 2011 Mar 15;17(6):1218-22
pubmed: 21288923
Nat Genet. 2006 Sep;38(9):1043-8
pubmed: 16921376
Cold Spring Harb Perspect Biol. 2012 Nov 01;4(11):
pubmed: 22888049
Ann Oncol. 2013 Aug;24(8):2048-56
pubmed: 23532114
Genes Chromosomes Cancer. 2006 Sep;45(9):874-81
pubmed: 16804918
N Engl J Med. 2017 Jun 1;376(22):2109-2121
pubmed: 28445112
Blood. 2010 Sep 2;116(9):1498-505
pubmed: 20519624
Mol Cell Biol. 2007 May;27(10):3682-94
pubmed: 17353269
Nat Rev Mol Cell Biol. 2010 Mar;11(3):220-8
pubmed: 20177397
Genome Res. 2013 Sep;23(9):1446-61
pubmed: 23796952
Cell. 2018 Sep 6;174(6):1347-1360
pubmed: 30193109
Eur J Haematol. 2015 Jul;95(1):3-15
pubmed: 25645650
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Nat Rev Mol Cell Biol. 2012 Dec;13(12):789-803
pubmed: 23175282
J Biol Chem. 2004 Mar 26;279(13):12997-3003
pubmed: 14722118
Nature. 2010 Feb 18;463(7283):899-905
pubmed: 20164920
PLoS One. 2011;6(7):e22114
pubmed: 21799775
Gut. 2016 Oct;65(10):1690-701
pubmed: 26156959
Cancer Res. 2018 Dec 1;78(23):6529-6535
pubmed: 30420473
J Clin Oncol. 2012 Jun 20;30(18):2256-64
pubmed: 22547595
Chromosoma. 2004 Jun;112(8):389-97
pubmed: 15156327
Gut. 2020 Apr;69(4):748-763
pubmed: 32034004
PLoS One. 2014 Jun 26;9(6):e100748
pubmed: 24968351
Oncogene. 2004 Nov 11;23(53):8597-602
pubmed: 15467761
Oncotarget. 2014 Feb 28;5(4):860-71
pubmed: 24658219
Mol Cell. 2016 Feb 18;61(4):520-534
pubmed: 26853146
BMC Cancer. 2008 Oct 29;8:314
pubmed: 18959792